At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 30 enrolled
Drug / intervention
Sotaterceptdrug
Likely dose
Sotatercept 0.3 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effect of Sotatercept on Central Cardiopulmonary Performance and Peripheral Oxygen Transport During Exercise in Pulmonary Arterial Hypertension
In Brief
A Phase 4 clinical trial evaluating Sotatercept for Pulmonary Arterial Hypertension. Completed, enrolled 30 participants across 1 site.
Detailed Summary
The purpose of this study is to see if the drug sotatercept given for 36 weeks improves the functioning of the heart and improves quality of life.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Arterial Hypertension
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
20252026
First PostedMay 2024
Enrollment StartJul 2024
Primary CompletionJan 2026
TodayJul 2026
First PostedMay 10, 2024
Enrollment StartJul 5, 2024
Primary CompletionJan 14, 2026
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 2.1 years ago
Interventions
Sotaterceptdrug
As per FDA indications, sotatercept will be administered as 0.3 mg/kg injection for the first dose followed by 0.7 mg/kg injections for subsequent doses.